Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement
Segments

Common Size IS
Op Efficiency
Credit Analysis

10x Genomics, Inc. (TXG)

Cash Flow Statement

Standardized | As Reported Annual | Quarterly | TTM
  Older >>
In millions, except per share itemsMar-31-23Jun-30-22Mar-31-22Dec-31-21Sep-30-21Jun-30-21Mar-31-21Dec-31-20
   10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K
Operating activities:          
    Net loss  -50.7-64.5-42.4-18.4-17.2-11.1-11.6-415.6
    Adjustments to reconcile net loss to net cash used in operating activities:          
        Stock-based compensation expense  42.136.326.026.926.026.916.214.3
        Depreciation and amortization  6.56.56.25.85.74.94.83.9
        Amortization of right-of-use assets  2.11.91.81.51.62.31.71.5
        Realized loss on marketable securities  1.7       
        Other  0.2 0.2     
        Changes in operating assets and liabilities:          
            Accounts receivable  26.30.38.7-6.8-19.4-1.6-6.2-15.2
            Inventory  -0.4-7.4-3.7-8.8-7.1-5.6-8.6-4.8
            Prepaid expenses and other current assets  -4.3-1.5-3.90.2-0.20.5-1.6-1.9
            Other noncurrent assets  -10.50.00.20.70.10.10.2-0.1
            Accounts payable  -0.87.42.9-1.12.5-1.210.9-4.5
            Accrued compensation and other related benefits  -15.15.3-13.34.56.14.41.34.2
            Deferred revenue  1.11.40.2 0.30.60.3 
            Accrued expenses and other current liabilities  -0.2-1.4-3.51.74.00.7-7.216.5
            Operating lease liability  -2.3-1.8-0.40.00.7-1.7-1.4-1.7
            Other noncurrent liabilities  0.30.20.2-0.60.2-0.8-3.5-0.6
                Net cash used in operating activities  -4.1-17.0-20.85.8-26.23.1-4.1-130.2
   
Investing activities:          
    Purchases of property and equipment  -4.6-27.2-28.1-27.6-20.2-14.6-38.9-21.3
    Acquisition of intangible assets  -0.7      -0.9
    Purchase of marketable securities   -29.2-242.3     
    Proceeds from sales of marketable securities  93.332.712.7     
    Proceeds from maturities of marketable securities  31.99.10.3     
        Net cash provided by (used in) investing activities  120.0-27.5-257.6-27.6-20.2-14.6-44.3-22.3
   
Financing activities:          
    Payments on financing arrangement  -5.8 -5.4   -5.00.0
    Issuance of common stock from exercise of stock options  2.46.47.88.96.716.28.58.5
        Net cash (used in) provided by financing activities  -3.46.42.48.96.716.23.57.7
Effect of exchange rate changes on cash, cash equivalents, and restricted cash  0.0 0.0     
    Net increase (decrease) in cash, cash equivalents, and restricted cash  112.4 -276.0     
   
Supplemental disclosures of cash flow information:          
    Cash paid for interest  0.4 0.8   1.2 
    Cash paid for taxes  2.50.42.90.30.51.06.80.1
    Noncash investing and financing activities:          
        Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities  30.711.715.04.35.24.72.8-11.2
        Right-of-use assets obtained in exchange for new operating lease liabilities  6.9 16.61.78.30.011.22.7
        Contingent consideration payable from business acquisition    1.5  0.01.5 

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy